A M Eggermont

Summary

Affiliation: Erasmus University Medical Center
Country: The Netherlands

Publications

  1. ncbi European approach to the treatment of malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Curr Opin Oncol 14:205-11. 2002
  2. ncbi The role of isolated limb perfusion for melanoma confined to the extremities
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Surg Clin North Am 83:371-84, ix. 2003
  3. ncbi Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, Netherlands
    Curr Oncol Rep 5:79-80. 2003
  4. ncbi The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer
    A M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 38:S114-9. 2002
  5. ncbi The role interferon-alpha in malignant melanoma remains to be defined
    A M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 37:2147-53. 2001
  6. ncbi The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer
    A M Eggermont
    EORTC Melanoma Group, Brussels, Belgium
    Ann Surg Oncol 8:38S-40S. 2001
  7. ncbi Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands E mail
    Curr Oncol Rep 3:359-67. 2001
  8. ncbi Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 2:563-9. 2002
  9. ncbi Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Den Hoed Cancer Center UHR DHCC, The Netherlands
    Hepatogastroenterology 47:776-81. 2000
  10. ncbi Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    J Clin Oncol 14:2653-65. 1996

Collaborators

Detail Information

Publications79

  1. ncbi European approach to the treatment of malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Curr Opin Oncol 14:205-11. 2002
    ..In Europe biochemotherapy is being abandoned and various less toxic or nontoxic approaches with vaccines and antiangiogenic agents are under study...
  2. ncbi The role of isolated limb perfusion for melanoma confined to the extremities
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Surg Clin North Am 83:371-84, ix. 2003
    ..TNF changes the pathophysiology, greatly enhances the uptake of Melphalan and destructs selectively the vasculature of large tumors. To date, ILP is not indicated in an adjuvant setting...
  3. ncbi Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, Netherlands
    Curr Oncol Rep 5:79-80. 2003
  4. ncbi The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer
    A M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 38:S114-9. 2002
    ..Each trial is associated with the appropriate translational research programmes...
  5. ncbi The role interferon-alpha in malignant melanoma remains to be defined
    A M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 37:2147-53. 2001
    ....
  6. ncbi The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer
    A M Eggermont
    EORTC Melanoma Group, Brussels, Belgium
    Ann Surg Oncol 8:38S-40S. 2001
    ..In addition, tumor-positive and tumor-negative SNs will be assessed for activated cytotoxic T lymphocytes and downregulation of dendritic cell functions...
  7. ncbi Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands E mail
    Curr Oncol Rep 3:359-67. 2001
    ..ILP is also a promising treatment modality for adenoviral vector-mediated gene therapy. Many clinical phase I/II evaluations in ILP are now underway...
  8. ncbi Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 2:563-9. 2002
    ..Since the impact of dose and duration of treatment also awaits further evaluation. It is reasonable to state that the role of interferon in melanoma still remains to be defined...
  9. ncbi Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Den Hoed Cancer Center UHR DHCC, The Netherlands
    Hepatogastroenterology 47:776-81. 2000
    ..These problems were addressed in a program aimed at developing a repeatable method of isolated perfusion of the liver with minimally invasive techniques...
  10. ncbi Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial
    A M Eggermont
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    J Clin Oncol 14:2653-65. 1996
    ....
  11. ncbi TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives
    A M Eggermont
    University Hospital Rotterdam, Daniel den Hoed Cancer Center, The Netherlands
    Anticancer Res 18:3899-905. 1998
    ..Here we present an overview of these developments...
  12. ncbi Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Centre, Groene Hilledijk 301, Rotterdam, The Netherlands
    Br J Cancer 83:1176-82. 2000
    ..A synergistic anti-tumour effect of L-NAME is observed in combination with melphalan and/or TNF using ILP. These results indicate a possible role of L-NAME for the treatment of solid tumours in a systemic or regional setting...
  13. ncbi Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats
    T L ten Hagen
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Cancer 87:829-37. 2000
    ..Regarding the effects of systemic administration of low doses of TNF-alpha, these findings may be important for enhanced tumor targeting of various liposomal drug formulations...
  14. ncbi In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats
    A H van der Veen
    Department of Surgery, University Hospital Rotterdam Dijkzigt, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Cancer 79:433-9. 1999
    ..The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable...
  15. ncbi Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, The Netherlands
    Br J Cancer 82:1000-3. 2000
    ....
  16. ncbi Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Cancer 80:161-6. 1999
    ..Moreover, the dose of TNF could be lowered to 10 microg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings...
  17. ncbi Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan
    I H Borel Rinkes
    Department of Surgical Oncology, Rotterdam Cancer Institute University Hospital Rotterdam, The Netherlands
    Br J Cancer 75:1447-53. 1997
    ..IHP with TNF-alpha with(out) melphalan in pigs is technically feasible, results in minimal systemic drug exposure and causes minor transient disturbances of liver biochemistry and histology...
  18. ncbi TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
    A H van der Veen
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    Br J Cancer 82:973-80. 2000
    ..As TNF-alpha by itself has no or only minimal effect on tumour growth, an increase in local concentrations of chemotherapeutic drugs might well be the main mechanism for the synergistic anti-tumour effects...
  19. ncbi Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel de Hoed Cancer Center, Rotterdam, The Netherlands
    Hum Gene Ther 12:489-502. 2001
    ....
  20. ncbi Research and quality control in surgical oncology
    P Therasse
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Surg Oncol Clin N Am 10:763-72, viii. 2001
    ....
  21. ncbi Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases
    A E van der Pool
    Division of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Surg 97:383-90. 2010
    ..This study evaluated the outcome of patients treated for rectal cancer and synchronous hepatic metastases in the era of effective induction radiotherapy and chemotherapy...
  22. ncbi Stromal influences on breast cancer cell growth
    C E van Roozendaal
    Division of Endocrine Oncology Department Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Br J Cancer 65:77-81. 1992
    ..The effects on cancer cell growth are, however, varying depending on the source of the stroma and the characteristics of the epithelial tumour cells...
  23. ncbi Randomized adjuvant therapy trials in melanoma: surgical and systemic
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Semin Oncol 34:509-15. 2007
    ..The population of patients that can benefit from IFN needs to be better defined by identifying new biomarkers by genomic and proteomic studies, which are ongoing...
  24. ncbi TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility
    Remco van Horssen
    Department of Surgical Oncology, Erasmus MC--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 11:397-408. 2006
    ..In addition, possible factors modulating TNF-alpha actions are discussed...
  25. ncbi Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study
    Sandra L Wong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:809-16. 2006
    ..CONCLUSIONS: This study underscores the importance of ongoing prospective randomized trials in determining the therapeutic value of CLND after positive SLN biopsy in melanoma patients...
  26. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  27. ncbi Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 106:1776-84. 2006
    ..CONCLUSION: TNF+M-based ILP can provide limb salvage in a significant percentage of patients with locally advanced STS and has therefore gained a permanent place in the multimodality treatment of STS...
  28. ncbi Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Nat Clin Pract Oncol 3:94-103. 2006
    ..It represents an important example of combination therapy that modulates the tumor vasculature and should be offered in high-volume tertiary referral centers...
  29. ncbi The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 106:156-62. 2006
    ..CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity...
  30. ncbi Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, Netherlands
    Lancet 366:1189-96. 2005
    ..Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients...
  31. ncbi Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats
    Flavia Brunstein
    Laboratory of Experimental Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    Acta Cir Bras 20:275-9. 2005
    ....
  32. ncbi Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Ulrich Keilholz
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    J Clin Oncol 23:6747-55. 2005
    ..This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma...
  33. ncbi Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Ann Surg Oncol 12:609-15. 2005
    ..Recurrences after ILP, however, occur in approximately 50% of patients and are a challenge for further treatment. The efficacy of repeat ILPs to prolong local control in this patient category is evaluated in this article...
  34. ncbi Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion
    Remco van Horssen
    Department of Surgical Oncology, Laboratory for Experimental Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 119:1481-90. 2006
    ..Analysis of EMAP-II expression in melanoma biopsies should be implemented in the ILP procedure...
  35. ncbi Randomized trials in melanoma: an update
    Alexander M M Eggermont
    Erasmus Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, EA 3075, Rotterdam, The Netherlands
    Surg Oncol Clin N Am 15:439-51. 2006
    ..Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs...
  36. ncbi Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated
    Marjolein Bannink
    Dept of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
    Psychosomatics 49:56-63. 2008
    ..The results of this study indicate that IFN-alpha treatment is not suitable as a study model for depression in general...
  37. ncbi Management of melanoma: a European perspective
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Surg Oncol Clin N Am 17:635-48, x. 2008
    ..Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival...
  38. ncbi Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma
    Cornelis Verhoef
    Department of Surgical Oncology, ErasmusMC Daniel den Hoed Cancer Center, 310 Groene Hilledijk, 3075 EA, Rotterdam, The Netherlands
    Curr Treat Options Oncol 8:417-27. 2007
    ..TNF-alpha-based ILP is a well-established treatment to avoid amputations. It represents an important example of tumor vascularity-modulating combination therapy and should be offered in large volume tertiary referral centers...
  39. ncbi TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective"
    Ann L B Seynhaeve
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Front Biosci 13:3034-45. 2008
    ..In this dual approach, TNF enhances intratumoral accumulation of the chemotherapeutic drug resulting in an impressive tumor response...
  40. ncbi Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response
    Ann L B Seynhaeve
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Res 67:9455-62. 2007
    ..We conclude that delivery of nanoparticulate drug formulations to solid tumor benefits from augmenting the vascular leakage through vascular manipulation with vasoactive drugs like TNF...
  41. ncbi Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 25:1562-9. 2007
    ..In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients...
  42. ncbi Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs
    Ferdy J Lejeune
    J Clin Oncol 25:1449-50; author reply 1450-1. 2007
  43. ncbi Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Ann Surg Oncol 14:795-801. 2007
    ..Because of its vasoactive properties, histamine (Hi) is an alternative to TNF. In this article we evaluate its potential synergistic effect in M-IHP, improving response rates...
  44. ncbi Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3000 DR Rotterdam, The Netherlands
    Anticancer Drugs 17:949-59. 2006
    ..g. interstitial fluid pressure and pH), we speculate that the tumor vascular changes, and concurrent hemorrhage and drug accumulation are the key explanations for the observed synergistic anti-tumor response...
  45. ncbi When to perform surgery in stage IV melanoma patients?
    Johannes H W de Wilt
    Onkologie 31:226-7. 2008
  46. ncbi Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 16:667-74. 2005
    ..In conclusion, combination therapy of Doxil and low-dose TNF seems attractive for the treatment of highly vascularized tumors, but also of intermediate vascularized tumors like the osteosarcoma...
  47. ncbi Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Melanoma Res 15:179-84. 2005
    ..001). Selective CLND is the recommended procedure for patients with cervical metastases of cutaneous melanoma. The number of positive lymph nodes significantly affects the outcome of the patients...
  48. ncbi European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Semin Oncol 29:382-8. 2002
    ..Less toxic lower-dose maintenance IFN regimens, antiangiogenic agents, and vaccine therapies are currently being explored...
  49. ncbi Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma
    Eva M Noorda
    Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Ann Surg Oncol 11:491-9. 2004
    ..Therefore, ILP could be a valuable adjunct to excisional surgery for in-transit metastases in these patients whose LRFIs tend to shorten over time...
  50. ncbi Tumor vascular therapy with TNF: critical review on animal models
    Timo L M ten Hagen
    Department of Surgical Oncology, Erasmus, The Netherlands
    Methods Mol Med 98:227-46. 2004
    ..In this chapter we will describe the use of specific animal models for efficacy studies, such as isolated limb perfusion and isolated liver perfusion in the rat...
  51. ncbi Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors
    Boudewijn van Etten
    Department of Surgical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 10:32-7. 2003
    ..CONCLUSIONS: Older patients should not be withheld a TNF-based ILP for limb salvage, because the procedure is safe and highly effective in these patients...
  52. ncbi Isolated hepatic perfusion: experimental evidence and clinical utility
    Johannes H W de Wilt
    Erasmus MC (University Medical Center Rotterdam)-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Surg Clin North Am 84:627-41. 2004
    ..Future research should be directed to the identification of suitable biological or chemotherapeutic agents, defining clinical indications, and development of technical modifications to make it more generally applicable...
  53. ncbi Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Lancet Oncol 4:429-37. 2003
    ..Moreover, isolated limb perfusion is an effective modality for gene therapy mediated by an adenoviral vector. Various clinical phase I-II studies can be expected in the next few years...
  54. ncbi Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients
    Arthur R Van Gool
    Department of Psychosocial Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE, Rotterdam, The Netherlands
    Psychiatry Res 119:125-32. 2003
    ..Changes in tryptophan metabolism may play a role in the pathophysiology of the neuropsychiatric side effects of IFN-alpha, and further research into the predictive potential of NEOP is warranted...
  55. ncbi Current status of interferon-alpha in the treatment of melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Chemother Biol Response Modif 22:729-37. 2005
  56. ncbi Management of melanoma patients: benefit of intense follow-up schedule is not demonstrated
    Philippe Autier
    J Clin Oncol 21:3707; author reply 3707-8. 2003
  57. ncbi TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas
    Dirk J Grunhagen
    Dept of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Cancer Treat Res 120:65-79. 2004
  58. ncbi Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Am J Clin Dermatol 4:531-6. 2003
    ..For now the role of interferon-alpha still remains to be determined and its use should be restricted to the setting of clinical trials...
  59. ncbi Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Res 65:4300-8. 2005
    ..The results in our study indicate that the novel combination of IL-2 and melphalan in ILP has synergistic antitumor activity and may be an alternative for ILP with TNF and melphalan...
  60. ncbi Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats
    Timo L M ten Hagen
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Cancer 97:115-20. 2002
    ..These results indicate that pegylated liposomal encapsulation may be effective in systemic application of TNF for combined treatment with liposomal chemotherapy of advanced solid tumors...
  61. ncbi Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Anticancer Res 25:743-50. 2005
    ....
  62. ncbi Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Ann Surg Oncol 12:473-9. 2005
    ..To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas...
  63. ncbi Lack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin
    Alexander H van der Veen
    Laboratory for Experimental Surgical Oncology, Room Ee 0102a, Department of Surgical Oncology, University Hospital Rotterdam-Dijkzigt/Daniel Den Hoed Cancer Center, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
    Cancer Invest 20:499-508. 2002
    ..Only the tested rat osteosarcoma tumor cells demonstrated a cell arrest in the G2 phase, which did not result in attenuation of the cytotoxicity of doxorubicin towards these cells...
  64. ncbi Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients
    Marjolein Bannink
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Prog Neuropsychopharmacol Biol Psychiatry 29:109-14. 2005
    ..In that case, increased platelet MAO activity reflects an increased number of mitochondria per platelet...
  65. ncbi One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases
    Dirk J Grunhagen
    Department of Surgical Oncology, Daniel den Hoed Cancer Center, PO Box 5201 3008, Rotterdam, Netherlands
    Ann Surg 240:939-47; discussion 947-8. 2004
    ..The aim of this study is to describe the experience with 100 TNF-based ILP for locally advanced melanoma and to determine prognostic factors for response, time to local progression, and survival...
  66. ncbi Isolated limb perfusion for unresectable melanoma of the extremities
    Eva M Noorda
    Department of Surgery, The Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam
    Arch Surg 139:1237-42. 2004
    ..Complete response rates are probably lower than the reported 54% for locoregional recurrent melanoma. In these patients, ILP with melphalan and tumor necrosis factor alpha (TNF-alpha) could be superior to ILP with melphalan alone...
  67. ncbi Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1603-10. 2004
    ..These results warrant further evaluation in the clinical ILP setting and, importantly, in organ perfusion...
  68. ncbi The development of optimal pathological assessment of sentinel lymph nodes for melanoma
    Martin G Cook
    Department of Histopathology, Royal Surrey County Hospital, Guildford, UK
    J Pathol 200:314-9. 2003
    ..The evolved protocol described here has been adopted by the EORTC as the standard procedure for pathological handling of sentinel lymph nodes for melanoma when SLN status is a criterion in their clinical trials or studies...
  69. ncbi Sentinel lymph-node false positivity in melanoma
    Alexander C J van Akkooi
    Department of Surgical Oncology, Erasmus University MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Nat Clin Pract Oncol 5:E2. 2008
  70. ncbi Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects
    Marjolein Bannink
    Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
    Neuropsychobiology 55:225-31. 2007
    ..The alterations in tryptophan metabolism might underlie the psychiatric side effects during treatment with IFN-alpha...
  71. ncbi Reaching first base in the treatment of metastatic melanoma
    Alexander M M Eggermont
    J Clin Oncol 24:4673-4. 2006
  72. ncbi Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes
    Remco van Horssen
    Laboratory of Experimental Surgical Oncology, Department of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytokine Growth Factor Rev 17:339-48. 2006
    ..We also discuss the different reported mechanisms for processing of proEMAP/p43 into EMAP-II. Finally, we speculate on the possible applications of this cytokine for (cancer) therapy...
  73. ncbi Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Laboratory of Experimental Surgical Oncology, Daniel den Hoed Cancer Centre, Room Ee 0175, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:573-80. 2007
    ..8-fold), or IL-2 only (3.5-fold) combined to melphalan. In vitro there was no synergy between the drugs. In conclusion there was a negative synergistic effect between IL-2 and Hi in the regional setting...
  74. ncbi Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness
    Alexander C J van Akkooi
    Erasmus University Medical Center-Daniel den Hoed Cancer Center, Department of Surgical Oncology, Rotterdam, The Netherlands
    Eur J Cardiothorac Surg 30:408-10. 2006
    ..Isolated limb perfusions without the use of any blood transfusion products are technically possible, but an adequate preoperative hemoglobin concentration is a prerequisite...
  75. ncbi Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations
    Arthur R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 15:587-91. 2004
    ....
  76. ncbi Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 40:1825-36. 2004
    ..Single-administration dacarbazine (850-1000 mg/m2), once every 3 weeks, is currently the standard reference therapy in patients with advanced melanoma. New effective therapies are urgently needed for this treatment-refractory disease...
  77. ncbi Preoperative radiotherapy improves outcome in recurrent rectal cancer
    Maarten Vermaas
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3008 Rotterdam, The Netherlands
    Dis Colon Rectum 48:918-28. 2005
    ..Preoperative radiotherapy should be standard treatment for patients with recurrent rectal cancer...
  78. ncbi Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics
    Peter Brouckaert
    Department of Molecular Biology, Flanders Interuniversity Institute of Biotechnology, Ghent University, Ghent, Belgium
    Int J Cancer 109:442-8. 2004
    ..These results imply that systemic application of clinically tolerable doses of TNF may improve drug distribution and tumor response and could be useful in a number of anti-cancer therapies...
  79. ncbi Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents
    Timo L M ten Hagen
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Hyperthermia 22:241-6. 2006
    ..Here some of the methodologies and drug combinations which improve solid tumour therapy through acting on the tumour pathophysiology are discussed...